Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Nanomedicine–lipoprotein interactions

Nature Reviews Bioengineering volume 3, pages 435–437 (2025)Cite this article

Subjects

Nanomedicines interact with lipoproteins in the blood, which might result in alterations in both nanomedicine and lipoprotein structure and function. Such interactions could also be exploited for site-specific delivery through a ‘lipoprotein Trojan Horse’ mechanism and to restore dysfunctional lipoproteins.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Nanomedicine-lipoprotein interactions.

References

  1. Shah, A. S., Tan, L., Long, J. L. & Davidson, W. S. Proteomic diversity of high-density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. 54, 2575–2585 (2013).

    Article  Google Scholar 

  2. Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282–300 (2023).

    Article  Google Scholar 

  3. Williams, K. J., Phillips, M. C. & Rodrigueza, W. V Structural and metabolic consequences of liposome-lipoprotein interactions. Adv. Drug Deliv. Rev. 32, 31–43 (1998).

    Article  Google Scholar 

  4. Courtney, H. S., Zhang, Y.-M., Frank, M. W. & Rock, C. O. Serum opacity factor, a streptococcal virulence factor that bind to apolipoproteins A-I and A-II and disrupts high density lipoprotein structure. J. Biol. Chem. 281, 5515–5521 (2006).

    Article  Google Scholar 

  5. Woodburn, K. & Kessel, D. The alteration of plasma lipoproteins by Cremophor EL. J. Photochem. Photobiol. 22, 197–201 (1994).

    Article  Google Scholar 

  6. Hamad, I., Hunter, A. C. & Moghimi, S. M. Complement monitoring of Pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. J. Control. Release 170, 167–174 (2013).

    Article  Google Scholar 

  7. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149–1157 (2007).

    Article  Google Scholar 

  8. Sobot, D. et al. Circulating lipoproteins: A Trojan horse guiding squalenoylated drugs to LDL-accumulating cancer cells. Mol. Ther. 25, 1596–1605 (2017).

    Article  Google Scholar 

  9. Michell, D. L. et al. Elucidation of physico-chemical principles of high-density lipoprotein-small RNA binding interactions. J. Biol. Chem. 298, 101952 (2022).

    Article  Google Scholar 

  10. Guevara, J. G. Jr., Kang, D. & Moore, J. P. Nucleic acid-binding properties of low-density lipoproteins: LDL as a natural gene vector. J. Protein Chem. 18, 845–857 (1999).

    Article  Google Scholar 

  11. Engelen, S. E. et al. Lipoproteins act as vehicles for lipid antigen delivery and activation of invariant natural killer T cells. JCI Insight 8, 158089 (2023).

    Article  Google Scholar 

  12. Szebeni, J. et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity. Int. Immunopharmacol. 1, 721–735 (2001).

    Article  Google Scholar 

  13. Wasan, K. M. et al. Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. J. Pharm. Pharmaceut. Sci. 6, 189–197 (2003).

    Google Scholar 

  14. Rosenson, R. S. et al. Dysfunctional and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. 13, 48–60 (2016).

    Article  Google Scholar 

  15. Kudinov, V. A. et al. High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis. Biomed. Pharmacother. 141, 111900 (2021).

    Article  Google Scholar 

Download references

Acknowledgements

S.M.M. acknowledges support by the European Union’s Horizon 2020 programme funded under H2020-EU.1.3. – Excellent Science – Marie Skłodowska-Curie Actions, grant agreement ID. 956544 (DIRNANO: Directing the immune response through designed nanomaterials). D.S. acknowledges support by the National Institutes of Health grant R01AI154959.

Author information

Authors and Affiliations

  1. School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK

    S. Moein Moghimi

  2. Translational and Clinical Research Institute, Faculty of Health and Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

    S. Moein Moghimi

  3. Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

    S. Moein Moghimi & Dmitri Simberg

  4. Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

    S. Moein Moghimi & Dmitri Simberg

  5. Translational Bio-Nanosciences Laboratory, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

    Dmitri Simberg

Authors
  1. S. Moein Moghimi
    View author publications

    Search author on:PubMed Google Scholar

  2. Dmitri Simberg
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to S. Moein Moghimi.

Ethics declarations

Competing interests

The authors declare no competing interests.

Peer review

Peer review information

Nature Reviews Bioengineering thanks Jan Grimm and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moghimi, S.M., Simberg, D. Nanomedicine–lipoprotein interactions. Nat Rev Bioeng 3, 435–437 (2025). https://doi.org/10.1038/s44222-025-00291-9

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s44222-025-00291-9

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research